Source: davit kirakosyan
Bernstein Maintains Outperform Rating on Gilead Sciences
In a recent update, Bernstein SocGen Group has reiterated its Outperform rating on Gilead Sciences (NASDAQ: GILD), a research-based biopharmaceutical company. The firm has also maintained its target price at $135. The decision was influenced by Gilead’s limited financial exposure to the recent developments in Medicaid pricing.
Medicaid Pricing Developments
In the ever-evolving financial landscape, one of the recent developments that have caught the attention of many investors has been the changes in Medicaid pricing. Medicaid, a joint federal and state program, helps with medical costs for some people with limited income and resources. Pricing changes in this space can significantly impact the revenues of biopharmaceutical companies like Gilead Sciences.
Bernstein’s report highlighted language indicating that only certain products, which constitute about 60% of Gilead’s portfolio, were aligning with the Most Favored Nation (MFN) pricing for Medicaid. The MFN pricing rule is a new policy that aims to lower prescription drug prices by aligning them with the lowest price that drug manufacturers offer in other developed countries. The rule’s implementation could potentially lead to a decrease in revenue for pharmaceutical companies.
Gilead’s Products Aligning with MFN Pricing
Following discussions with Gilead, Bernstein confirmed that the primary products aligning with MFN pricing were Genvoya and Odefsey. These are HIV treatments that together generated approximately $750 million in Medicaid gross spend in 2023.
Genvoya, a once-daily single tablet regimen for the treatment of HIV-1 infection, was approved by the FDA in 2015. Odefsey, on the other hand, received its FDA approval in 2016. Both drugs have been significant contributors to Gilead’s revenue.
Impact on Gilead’s Revenue
The analyst at Bernstein said this confirmation alleviated concerns around Medicaid pricing risk for Biktarvy, another HIV drug from Gilead, which Bernstein had viewed as the key area of uncertainty. The firm had initially anticipated that changes in the Medicaid pricing could pose a risk to the revenues generated from Biktarvy.
However, it was found that the negotiations resulted in a favorable outcome for Gilead. Bernstein’s report suggests that the estimated 2026 revenue impact due to the Medicaid pricing changes is expected to be minimal. It is estimated to be less than $200 million for Genvoya and Odefsey combined, which is in the low single-digit percentage range for the overall company.
This is a significant relief for the biopharmaceutical company, as any substantial hit to its revenue could have adverse effects on its growth trajectory and financial health. It also allows Gilead to continue focusing on its core operations and innovative research without worrying about the financial impact of the new Medicaid pricing.
Conclusion
In conclusion, Gilead’s limited exposure to the recent Medicaid pricing changes has led to Bernstein SocGen Group maintaining its Outperform rating and $135 price target on Gilead Sciences. The firm’s analysis suggests that the impact of these pricing changes will be minimal on Gilead’s revenue, which is a favorable outcome for the company. This development is likely to affect the investment decisions of many investors who closely follow the pharmaceutical industry and companies like Gilead Sciences.